Makes a precisely shaped dry powder drug for lung disease that only its own factory can produce.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
Makes a precisely shaped dry powder drug for lung disease that only its own factory can produce.
What this company is and how it runs — written from structure, not news.
Liquidia Corporation makes an inhaled dry powder treatment for pulmonary hypertension called Yutrepia, using a mold-based process called PRINT that shapes each treprostinil particle to an exact geometry — and because where the particle lands in the lung determines how much drug actually reaches the bloodstream, the particle shape is effectively the dose itself. The FDA approved Yutrepia based on data from particles made by that specific mold sequence at Liquidia's single facility in Morrisville, North Carolina, which means the manufacturing process and the regulatory approval are registered to each other: a competitor that bought the same equipment would still be making an unapproved particle and would have to run a full clinical program from scratch. All of Liquidia's output is therefore capped by whatever that one Morrisville facility can produce, since the PRINT equipment cannot be handed to a contract manufacturer without repeating the entire qualification and approval process. If a manufacturing inspection shut down Morrisville, or if the FDA required a change to the particle design, the same co-registration that protects Yutrepia from competition would work against the company — every corrective step would require new comparability data, with no backup facility able to keep production running in the meantime.
How does this company make money?
The main source of revenue is prescription sales of Yutrepia, sold through specialty pharmacies, with the price paid depending on each patient's insurance coverage and whether they qualify for patient assistance programs. The company also earns milestone payments and ongoing royalties when it licenses the PRINT technology to other pharmaceutical companies developing drugs in different disease areas.
What makes this company hard to replace?
Patients who use Yutrepia have been trained on the specific dry powder inhaler device it uses; switching to a different prostacyclin therapy means learning a completely different device and technique. The PRINT-manufactured particles cannot be substituted by a generic because FDA rules do not allow generic substitution for this type of product. Patients who switch also have to go through a new dose-titration process with their doctor, since the dosing profile of the dry powder formulation differs from alternatives like inhaled or intravenous prostacyclin therapies.
What limits this company?
The Morrisville facility is the only place in the world with the clean-room equipment and FDA-validated process needed to make Yutrepia particles. Those particles cannot be handed off to a standard drug contract manufacturer — doing so would require starting the regulatory qualification process over from scratch. However much output that one facility can produce is the ceiling.
What does this company depend on?
The company cannot operate without the PRINT manufacturing platform and its associated intellectual property, the FDA approval for Yutrepia, the United Therapeutics licensing agreement that supplies the treprostinil active drug ingredient, specialty pharmacy distribution networks that serve pulmonary hypertension patients, and clinical-grade dry powder inhalation devices.
Who depends on this company?
Pulmonologists treating pulmonary arterial hypertension patients would lose the only inhaled treprostinil dry powder option and would have to switch patients to different prostacyclin delivery methods. Specialty pharmacies that fill Yutrepia prescriptions would lose a key therapy from their pulmonary hypertension offerings. Clinical research sites using PRINT-based particle engineering in drug trials would need to find alternative platforms.
How does this company scale?
Once a PRINT particle design and formulation protocol has been developed for one therapy, those templates and protocols can be adapted for other inhaled drug programs without starting entirely from scratch — so the pipeline can grow without rebuilding the science each time. What does not get cheaper or easier as the company grows is the physical manufacturing: the specialized PRINT equipment and clean-room space in Morrisville cannot be outsourced, so every additional unit of output requires more capacity at that same constrained facility.
What external forces can significantly affect this company?
Medicare Part D coverage decisions set how much patients and insurers pay for specialty pulmonary hypertension drugs, directly affecting how many patients can afford Yutrepia. If the FDA issues new guidance on inhaled drug delivery devices, the company could be forced into reformulation or additional clinical trials, both of which are expensive and slow. If the supply of treprostinil active ingredient from United Therapeutics were disrupted, production would stop because there is no alternative source built into the process.
Where is this company structurally vulnerable?
If the FDA inspected the Morrisville facility and issued a consent decree — or if it required reformulation of inhaled treprostinil — the company would have no backup. Every fix would require new comparability data tied to the same locked process, and there is no second facility or outside manufacturer already qualified to keep production running while repairs happen.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in6 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned: the close sits in the upper portion of the 52-week high-low range (range-position-1y elevated), ADX directional-movement asymmetry is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Three observations have aligned in the up direction: the higher-lows-pattern observation is firing, the ADX observation (sustained directional-movement asymmetry) is in the upper portion of its mapped range, and the OBV-trending-up observation is firing.
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Three present-state technical observations co-occur: Parabolic SAR is in its rising-state branch with close above the SAR level, the 14-period weekly RSI is at or above 70, and the recent 10-week ATR sits meaningfully above the prior 10-week ATR. The configuration describes rising-bias SAR, elevated RSI position, and expanding short-window volatility.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
Three observations have aligned: ADX directional-movement asymmetry is elevated, the volume-weighted returns observation is net positive over its lookback, and OBV is trending up over its lookback. The volume observation point up; ADX itself is direction-agnostic.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash position impresses, but the liability side stands alongside it. Cash weight is elevated while long-term debt is large relative to equity and total debt is large relative to trailing operating cash flow. The apparent cash strength is gross, not net of the debt that may have funded it.
Where is this company structurally exposed?
Three leverage observations have converged at elevated readings: debt is large relative to equity, large relative to total assets, and large relative to trailing operating cash flow. The capital structure is leveraged on three different denominators at once.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph